Center on Health Equity & Access

Clinical

Health Care Cost

Health Care Delivery

Insurance

Policy

Technology

Value-Based Care

News

All News

Press Releases

Product Approvals and Launches

Video

All Video Types

AJMC TV

Guidelines

Insights

OnLocation

Payer Perspectives

Peer Exchange

Post Conference Perspectives

Stakeholder Summit

Podcasts

Conferences

Conference Coverage

Conference Listing

Journals

All Journals

The American Journal of Managed Care

Population Health, Equity & Outcomes

Evidence-Based Oncology

About Supplements and Featured Publications

Supplements and Featured Publications Issues

Submit a Manuscript

Events

Institute for Value-Based Medicine

Patient-Centered Oncology Care

Resources

Interactive Tools

Formulary Central

Clinical Spotlight

Microsites

About AJMC

AJMC Staff

Anniversary

Seema Sonnad Award

Strategic Alliance Partners

Subscribe

Skylar is an associate editor for The American Journal of Managed Care® (AJMC®) and The Center for Biosimilars®, and joined AJMC® in 2020. She is responsible for covering all aspects of the ever-changing global biosimilar industry and produces content that is accessible and informative for all health care stakeholders.

She has a BA in journalism and media studies from Rutgers University. You can connect with Skylar on 

Articles

A new review explores the complexities of cow's milk allergy in breastfed infants, including symptoms, diagnosis challenges, and the impact of maternal diet.

Cow’s Milk Allergy in Breastfed Infants: What Clinicians and Families Need to Know

 in 2023, where she produces written content covering multiple disease states.

She has a BA in journalism from Seton Hall University. You can connect with Brooke on 

Videos

The newly approved linvoseltamab (Lynozyfic; Regeneron) has a manageable safety profile, along with a patient-friendly dosing schedule that includes intravenous administration, step-up dosing, and de-escalation to monthly maintenance.

Linvoseltamab Approval Offers New Off-the-Shelf Option for Heavily Pretreated Multiple Myeloma: Hans Lee, MD

Pediatric patients with multiple sclerosis (MS) face significant challenges transitioning to adult care, risking treatment delays and long-term health outcomes.

Review Highlights Gaps in Transition From Pediatric to Adult MS Care

New research identifies diabetes as an independent predictor of major adverse cardiovascular events in patients with both psoriasis and coronary artery disease.

Diabetes Increases Cardiovascular Risk in Patients With Psoriasis, Coronary Artery Disease

The American Journal of Managed Care provides insights into the latest news and research in managed care across multimedia platforms.

About

Contact

Editorial Boards

Advertise

Do Not Sell My Information

Terms & Conditions

Privacy Policy

AJMC - Managed Care News, Research, and Expert Insights

Facebook

Twitter

LinkedIn

Instagram

Specialty Area

Biosimilars

Cardiorenalmetabolic

Dermatology

Gastroenterology

Hematology

Hepatology

Immunology

Infectious Disease

Mental Health

Neurology

Obesity

Oncology

Ophthalmology

Pulmonology

Rare Disease

Respiratory

Rheumatology

Women's Health

Spotlight

Free In-Person Regional Events Focused on Oncology and Population Health

Topics

Digital Health

Formulary

Gene Therapy

Health Care Administration

Population Health

All Coverage

Event Coverage

Interviews

AJMC Journals

Author Forms

Authors

Nominate a Rising Leader

View

This Clinical Brief is supported by Boehringer Ingelheim.

This article provides an overview of generalized pustular psoriasis (GPP) and its clinical and economic impact, and reviews findings of Effisayil

 2, the first trial to study subcutaneous Spevigo

 (spesolimab-sbzo) in patients with GPP when not experiencing a flare.

Generalized pustular psoriasis (GPP) is a rare, severe skin condition with significant clinical and economic burdens. The Effisayil® 2 trial is the first to evaluate the efficacy of subcutaneous Spevigo® (spesolimab-sbzo) in GPP patients during non-flare periods. This study aims to provide insights into the management of GPP, potentially improving patient outcomes and reducing healthcare costs. The trial's findings could influence future treatment protocols and offer a new therapeutic option for GPP patients, addressing an unmet need in dermatological care.

Role of Spevigo® (spesolimab-sbzo) Injection in the Treatment of Generalized Pustular Psoriasis

Supplements and Featured Publications